

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/039549 A1

(51) International Patent Classification⁷: **A61K 31/00,**
31/496, 31/517, A61P 25/00, 25/28

ZIMMERMANN, Kaspar [CH/CH]; Am Chatzebach 4,
CH-4104 Oberwil (CH).

(21) International Application Number:
PCT/EP2004/012082

(74) Agent: **GRUBB, Phillip;** Novartis AG, Corporate Intellectual
Property, CH-4002 Basel (CH).

(22) International Filing Date: 26 October 2004 (26.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0325032.1 27 October 2003 (27.10.2003) GB
0325176.6 28 October 2003 (28.10.2003) GB

(71) Applicant (for all designated States except AT, US): **NO-**
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AUBERSON,**
Yves [CH/CH]; Maiengasse 4, CH-4123 Allschwil (CH).
BILBE, Graeme [GB/CH]; Chemin de Maujobia 37,
CH-2000 Neuchâtel (CH). **KUHN, Rainer, R. [DE/CH];**
Haselrain 75, 4125 Riehen (CH). **VON MATT, Pe-**
ter [CH/CH]; Fichtlirain 38, 4105 Biel-Benken (CH).
RUEGER, Heinrich [CH/CH]; Alemannenweg 6,
4112 Fluh (CH). **STAUFENBIEL, Matthias [DE/DE];**
Müllerweg 7, 79541 Lörrach (DE). **WAGNER, Jürgen**
[DE/CH]; Nussbaumweg 24, CH-4103 Bottmingen (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR
DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION**



(I)

(57) **Abstract:** The invention relates to the use of an inhibitor of formula (I), or a pharma-
ceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta,
PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or
on a combination of the above enzymes, for the treatment and/or prevention of neurological
and vascular disorders related to beta-amyloid generation and/or aggregation such as neu-
rodegenerative diseases like Down's Syndrome, memory and cognitive impairment, dementia,
amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or
cerebral hemorrhage with amyloidosis.